supp.fit

S-Adenosyl Methionine: study protocols

22 study groups say how much S-Adenosyl Methionine participants took a day. These are the doses the studies gave. They are not a recommendation.

S-Adenosyl Methionine: what the research found →

Dose per serving from products

109 products in our catalogue print how much S-Adenosyl Methionine a serving holds.

Most common: 250 mg to 500 mg, 34% of 109 products.

Dose per servingProducts
25 mg or less
6
25 mg to 50 mg
21
50 mg to 100 mg
11
100 mg to 250 mg
34
250 mg to 500 mg
37

Dose per serving from research

22 study groups in 18 studies say how much S-Adenosyl Methionine participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 1 g to 2.5 g, 55% of 22 study groups.

Daily doseStudy groups
100 mg to 250 mg
2
250 mg to 500 mg
3
500 mg to 1 g
4
1 g to 2.5 g
12
over 2.5 g
1

Commonly used together

7 of 22 study groups took S-Adenosyl Methionine with something else, but nothing that 3 or more different studies gave.

22 study groups

Study
S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial
1999 · AdoMet · Patients with alcoholic liver cirrhosis, Child classes A, B, or C
1.2 g2 years62
S-Adenosylmethionine (SAMe) monotherapy for depression: an 8-week double-blind, randomised, controlled trial
2020 · SAMe · Adults with DSM-5 major depressive disorder and mild-to-moderate depressive symptoms (MADRS score 14–25), not currently taking antidepressants
800 mg8 weeks—
S-adenosyl-methionine and betaine improve early virological response in chronic hepatitis C patients with previous nonresponse
2010 · Group B · Adults aged 18–65 with chronic hepatitis C and previous nonresponse to interferon/ribavirin combination treatment
1.2 g48 weeks17
S-adenosyl-methionine and betaine improve early virological response in chronic hepatitis C patients with previous nonresponse
2010 · Group A · Adults aged 18–65 with chronic hepatitis C and previous nonresponse to interferon/ribavirin combination treatment
1.2 g49 weeks16
Efficacy and tolerability of oral and intramuscular S-adenosyl-L-methionine 1,4-butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies
2002 · Oral SAMe (MC3) · Patients with major depressive episode and baseline 21-item HAM-D score ≥18
1.6 g6 weeks143
Comparative clinical trial of S-adenosylmethionine versus nabumetone for the treatment of knee osteoarthritis: an 8-week, multicenter, randomized, double-blind, double-dummy, Phase IV study in Korean patients
2009 · SAMe 400 mg TID · Korean adults over 18 years with knee osteoarthritis
1.2 g8 weeks67
S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial. [ISRCTN36233495]
2004 · SAMe treatment phase · Adults aged 40 or older with osteoarthritis of the knee
1.2 g8 weeks56
S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial
2010 · adjunctive SAMe · Serotonin reuptake inhibitor nonresponders with major depressive disorder
1.6 g6 weeks—
Dose increase of S-Adenosyl-Methionine and escitalopram in a randomized clinical trial for major depressive disorder
2020 · SAMe increased-dose group (week 7–12; nonresponders) · Adults aged 18–80 of both sexes with major depressive disorder who had not responded to the initial treatment dose at week 6
3.2 g6 weeks—
Dose increase of S-Adenosyl-Methionine and escitalopram in a randomized clinical trial for major depressive disorder
2020 · SAMe unchanged-dose group (week 7–12; responders) · Adults aged 18–80 of both sexes with major depressive disorder who responded to the initial treatment dose by week 6
1.6 g6 weeks—
Double-blind, placebo-controlled study of S-adenosyl-L-methionine in depressed postmenopausal women
1993 · SAMe · Women aged 45–59 with DSM-III-R major depressive disorder or dysthymia, 6–36 months after natural menopause or hysterectomy
1.6 g30 days—
Oral Administration of S-Adenosylmethionine (SAMe) and Lactobacillus Plantarum HEAL9 Improves the Mild-To-Moderate Symptoms of Depression: A Randomized, Double-Blind, Placebo-Controlled Study
2020 · SAMe plus L. plantarum HEAL9 · Adults aged 18–60 with subthreshold or mild-to-moderate depression
200 mg6 weeks46
Efficacy of a food supplement based on S-adenosyl methionine and probiotic strains in subjects with subthreshold depression and mild-to-moderate depression: A monocentric, randomized, cross-over, double-blind, placebo-controlled clinical trial
2022 · Food supplement · People with subthreshold depression or mild-to-moderate depression
200 mg90 days—
A randomized, double blind, placebo controlled trial of intravenous loading with S-adenosylmethionine (SAM) followed by oral SAM therapy in patients with knee osteoarthritis
1994 · S-adenosylmethionine (SAM) · Patients with symptomatic knee osteoarthritis; age and sex not specified
600 mg4 weeks—
A vitamin/nutriceutical formulation improves memory and cognitive performance in community-dwelling adults without dementia
2010 · NF group, 3-month blinded trial · Community-dwelling adults aged 18–86 years, both sexes, without dementia or clinical memory difficulties
400 mg90 days59
A vitamin/nutriceutical formulation improves memory and cognitive performance in community-dwelling adults without dementia
2010 · Open-label NF group, separate 6-month trial · Community-dwelling adults, both sexes, without dementia or clinical memory difficulties
400 mg26 weeks38
A vitamin/nutriceutical formulation improves memory and cognitive performance in community-dwelling adults without dementia
2010 · NF group, 2-week blinded trial · Community-dwelling adults, both sexes, without dementia or clinical memory difficulties
400 mg2 weeks—
Dietary supplement S-adenosyl-L-methionine (AdoMet) effects on plasma homocysteine levels in healthy human subjects: a double-blind, placebo-controlled, randomized clinical trial
2009 · AdoMet · Healthy human volunteers
800 mg4 weeks—
Bioavailability of S-adenosyl methionine and impact on response in a randomized, double-blind, placebo-controlled trial in major depressive disorder
2012 · SAMe arm · Adults with major depressive disorder who had not responded to serotonin-reuptake inhibitors; mean age 55 years, 50% female
1.6 g6 weeks20
A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-l-methionine in the treatment of gestational cholestasis
2004 · S-adenosyl-l-methionine · Women at less than 36 weeks of gestation with severe gestational cholestasis
1 g—22
S-adenosyl-L-methionine treatment for alcoholic liver disease: a double-blinded, randomized, placebo-controlled trial
2011 · SAM group · Adults with alcoholic liver disease and a history of chronic alcohol abuse
1.2 g24 weeks18
Oral S-adenosylmethionine in the symptomatic treatment of intrahepatic cholestasis. A double-blind, placebo-controlled study
1990 · S-adenosylmethionine group · Adults with chronic liver disease (26% chronic active hepatitis, 68% cirrhosis, 6% primary biliary cirrhosis) and elevated serum bilirubin and alkaline phosphatase
1.6 g——